Abstract
Human medicines European public assessment report (EPAR): Vyxeos liposomal (previously known as Vyxeos), daunorubicin / cytarabine, Leukemia, Myeloid, Acute, Date of authorisation: 23/08/2018, Revision: 2, Status: Authorised
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have